Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN
dc.contributor.author | Trukhin, Dmytro | |
dc.contributor.author | Saito, Haruhiro | |
dc.contributor.author | Goldman, Jonathan W. | |
dc.contributor.author | Garassino, Marina Chiara | |
dc.contributor.author | Chen, Yuanbin | |
dc.contributor.author | Reinmuth, Niels | |
dc.contributor.author | Hotta, Katsuyuki | |
dc.contributor.author | Poltoratskiy, Artem | |
dc.contributor.author | Hochmair, Maximilian J. | |
dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
dc.contributor.author | Ji, Jun Ho | |
dc.contributor.author | Statsenko, Galina | |
dc.contributor.author | Voitko, Oleksandr | |
dc.contributor.author | Conev, Nikolay V. | |
dc.contributor.author | Bondarenko, Igor | |
dc.contributor.author | Spencer, Stuart | |
dc.contributor.author | Xie, Mingchao | |
dc.contributor.author | Jones, Stephanie | |
dc.contributor.author | Franks, April | |
dc.contributor.author | Shrestha, Yashaswi | |
dc.contributor.author | Paz-Ares, Luis | |
dc.date.accessioned | 2021-12-10T12:24:43Z | |
dc.date.available | 2021-12-10T12:24:43Z | |
dc.identifier.citation | Saito H., Goldman J. W. , Garassino M. C. , Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., Trukhin D., Hochmair M. J. , ÖZGÜROĞLU M., et al., "Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN", ANNALS OF ONCOLOGY, cilt.32, 2021 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_bafeebb5-f888-44d5-8230-3acc07333578 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/173829 | |
dc.identifier.uri | https://doi.org/10.1016/j.annonc.2021.05.537 | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Oncology | |
dc.subject | Health Sciences | |
dc.title | Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN | |
dc.type | Makale | |
dc.relation.journal | ANNALS OF ONCOLOGY | |
dc.contributor.department | Kanagawa Canc Ctr , , | |
dc.identifier.volume | 32 | |
dc.contributor.firstauthorID | 2707039 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Makale [92796]